CN1246326C - 化合物菠萝黄酮苷及用途 - Google Patents
化合物菠萝黄酮苷及用途 Download PDFInfo
- Publication number
- CN1246326C CN1246326C CN 200410009055 CN200410009055A CN1246326C CN 1246326 C CN1246326 C CN 1246326C CN 200410009055 CN200410009055 CN 200410009055 CN 200410009055 A CN200410009055 A CN 200410009055A CN 1246326 C CN1246326 C CN 1246326C
- Authority
- CN
- China
- Prior art keywords
- pineapple
- glucopyranoside
- beta
- trimethoxyflavone
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 235000007119 Ananas comosus Nutrition 0.000 title claims abstract description 43
- 229930182486 flavonoid glycoside Natural products 0.000 title claims abstract description 20
- 241000234671 Ananas Species 0.000 title claims abstract description 15
- -1 flavonoid glycoside compound Chemical class 0.000 title abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 17
- 108010007622 LDL Lipoproteins Proteins 0.000 claims abstract description 14
- 102000007330 LDL Lipoproteins Human genes 0.000 claims abstract description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 8
- 230000003647 oxidation Effects 0.000 claims abstract description 8
- 238000007254 oxidation reaction Methods 0.000 claims abstract description 8
- 201000010099 disease Diseases 0.000 claims abstract description 7
- 238000002360 preparation method Methods 0.000 claims description 22
- 239000003814 drug Substances 0.000 claims description 18
- 150000007955 flavonoid glycosides Chemical class 0.000 claims description 16
- 239000000126 substance Substances 0.000 claims description 8
- 208000029078 coronary artery disease Diseases 0.000 abstract description 3
- 238000002474 experimental method Methods 0.000 abstract description 3
- 201000001320 Atherosclerosis Diseases 0.000 abstract description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 2
- 230000037356 lipid metabolism Effects 0.000 abstract description 2
- 230000000144 pharmacologic effect Effects 0.000 abstract description 2
- 238000001727 in vivo Methods 0.000 abstract 1
- 150000002978 peroxides Chemical class 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 30
- 244000099147 Ananas comosus Species 0.000 description 29
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- 239000007788 liquid Substances 0.000 description 19
- 239000000284 extract Substances 0.000 description 14
- 239000000463 material Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 10
- 238000010828 elution Methods 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- 239000002504 physiological saline solution Substances 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 8
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 230000006837 decompression Effects 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000002000 high resolution fast-atom bombardment mass spectrometry Methods 0.000 description 8
- 230000002829 reductive effect Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- 102000015779 HDL Lipoproteins Human genes 0.000 description 6
- 108010010234 HDL Lipoproteins Proteins 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 5
- 239000003463 adsorbent Substances 0.000 description 5
- 238000000502 dialysis Methods 0.000 description 5
- 238000004090 dissolution Methods 0.000 description 5
- 238000001035 drying Methods 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 239000003292 glue Substances 0.000 description 5
- 238000001556 precipitation Methods 0.000 description 5
- 239000011347 resin Substances 0.000 description 5
- 229920005989 resin Polymers 0.000 description 5
- 230000000452 restraining effect Effects 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 229910052710 silicon Inorganic materials 0.000 description 5
- 239000010703 silicon Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 4
- 239000012141 concentrate Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 230000000630 rising effect Effects 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000001629 suppression Effects 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 108010071584 oxidized low density lipoprotein Proteins 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- FFRBMBIXVSCUFS-UHFFFAOYSA-N 2,4-dinitro-1-naphthol Chemical compound C1=CC=C2C(O)=C([N+]([O-])=O)C=C([N+]([O-])=O)C2=C1 FFRBMBIXVSCUFS-UHFFFAOYSA-N 0.000 description 1
- GUMOJENFFHZAFP-UHFFFAOYSA-N 2-Ethoxynaphthalene Chemical group C1=CC=CC2=CC(OCC)=CC=C21 GUMOJENFFHZAFP-UHFFFAOYSA-N 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 241000234673 Bromelia Species 0.000 description 1
- 101100165177 Caenorhabditis elegans bath-15 gene Proteins 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 101800004637 Communis Proteins 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229920002538 Polyethylene Glycol 20000 Polymers 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 238000009954 braiding Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000012154 double-distilled water Substances 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 210000003725 endotheliocyte Anatomy 0.000 description 1
- 230000003628 erosive effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 230000003068 static effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Landscapes
- Medicines Containing Plant Substances (AREA)
- Saccharide Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
化合物菠萝黄酮苷及用途,涉及从菠萝叶中提取的一组新颖的化合物菠萝黄酮苷及其在医疗方面的用途。经药理实验表明,该组化合物具有明显的抗氧化和抑制氧化型低密度脂蛋白升高的作用,可用来治疗体内过氧化物升高所引起的病症,以及低密度脂蛋白升高所引起的相关性疾病,如脂代谢紊乱,动脉粥样硬化,冠心病等。
Description
技术领域
本发明涉及一组新颖的化合物菠萝黄酮苷及其制备和制药的用途,具体说是从菠萝叶中分离制备的新颖的化合物菠萝黄酮苷,以及该化合物在制备治疗体内过氧化物升高、氧化型低密度和高密度脂蛋白升高所引起的多种疾病的药物中的应用。
背景技术
菠萝,为凤梨科植物凤梨Ananas comosus(L.)Merr.[Bromelia comosa L.;A.sativusSchult.Et Schult.f.]的果实,又称菠萝。原产美洲,现广植于热带地区,我国福建、广东、海南、广西、云南等地均有种植。本品始载于清.吴其睿《植物名实图考》,以露兜子为名。该书记载:“露兜子产广东,一名波罗,生山野间,实如萝卜,上生叶一簇,尖长深齿,味色香具佳。果熟金黄色,皮坚如鱼鳞状,去皮食肉,香甜无渣,六月熟”。
古时对于菠萝叶无明确记载,现代人们常用菠萝叶纤维为编织和造纸的原料(《中国高等植物图鉴.第5册》科学出版社1976)。近时有记载菠萝叶具有消食和胃,止泻的功效,主治夏日暑泻,消化不良,胃脘胀痛等(《中华本草.第8卷》上海科学技术出版社1999)。
菠萝叶作为药用的记载比较少见,尤其是未见报道菠萝黄酮苷在治疗体内过氧化物过多、氧化型低密度或氧化型高密度脂蛋白升高等疾病的作用。
发明内容
本发明的目的是提供一组新的具有药用价值的化合物菠萝黄酮苷及其在医疗方面的用途。
具体地说是本发明提供的化合物菠萝黄酮苷,其结构通式如(I)所示:
其中:
R1=H R2=O-β-D-Glc
R1=OCH3 R2=O-β-D-Glc
R1=OH R2=O-β-D-Glc
R1=O-β-D-Glc R2=OH
所述的新化合物菠萝黄酮苷的理化性质及其各种波谱特征如下:
菠萝黄酮苷A(ananaflavoside A,5,4′-dihydroxy-7,3′,5′-trimethoxyflavone-4′-O-β-D-glucopyranoside):黄色粉末,mp196-198℃;
UV(MeOH)nm:321,273,220;
HRFABMS:m/z507.1490[M+1]+(calcd for C24H27O12,507.1496);
1H-NMR(DMSO-d6):12.86(OH-5),7.37(H-2′,6′),7.14(H-3),6.78(H-8)6.39(H-6),5.15(H-1″),3.88(OCH3-3′,5′),3.87(OCH3-7);
13CNMR(DMSO-d6):163.3(C-2),104.8(C-3),182.1(C-4),161.1(C-5),98.1(C-6),165.3(C-7),92.9(C-8),157.5(C-9),105.0(C-10),121.5(C-1′),104.3(C-2′),148.2(C-3′),137.7(C-4′),148.2(C-5′),104.3(C-6′),101.9(C-1″),74.1(C-2″),76.6(C-3″),69.8(C-4″),77.4(C-5″),60.7(C-6″),56.1(OCH3-7),56.7(OCH3-3′,5′)。
菠萝黄酮苷B(ananaflavoside B,5,4′-dihydroxy-6,7,3′,5′-tetramethoxyflavone-4′-O-β-D-glucopyranoside)黄色粉末,mp206-207℃;
UV(MeOH)nm:328,281,220;
HRFABMS:m/z 537.1607[M+1]+(calcd for C25H29O13,537.1602);
1HNMR(DMSO-d6):12.84(OH-5),7.38(H-2′,6′),7.14(H-3),7.02(H-8),5.15(H-1″),3.87(OCH3-7),3.89(OCH3-3′,5′),3.60(OCH3-6);
13C NMR(DMSO-d6):163.2(C-2),104.6(C-3),182.3(C-4),152.9(C-5),131.9(C-6),158.7(C-7),91.8(C-8),152.7(C-9),105.2(C-10),125.5(C-1′),104.9(C-2′),152.8(C-3′),137.6(C-4′),152.8(C-5′),104.9(C-6′),101.8(C-1″),74.1(C-2″),76.5(C-3″),69.8(C-4″),77.4(C-5″),60.7(C-6″),60.0(OCH3-6),56.5(OCH3-7),56.7(OCH3-3′,5′)。
菠萝黄酮苷C(ananaflavoside C,5,6,4′-trihydroxy-7,3′,5′-trimethoxyflavone-4′-O-β-D-glucopyranoside)黄色粉末,mp153-155℃;
UV(MeOH)nm:329,221,219;
HRFABMS:m/z523.1443[M+1]+(calcd for C24H27O13,523.1446);
1H-NMR(DMSO-d6):12.56(OH-5),8.76(OH-6),7.37(H-2′,6′),7.09(H-3),7.00(H-8),5.14(H-1″),3.93(3H,s,OCH3-7),3.89(OCH3-3′,5′);
13CNMR(DMSO-d6):162.9(C-2),104.4(C-3),182.3(C-4),146.0(C-5),130.0(C-6),154.4(C-7),91.3(C-8),149.7(C-9),105.1(C-10),125.2(C-1′),104.8(C-2′),152.8(C-3′),137.5(C-4′),152.8(C-5′),104.8(C-6′),101.9(C-1″),74.1(C-2″),76.5(C-3″),69.8(C-4″),77.4(C-5″),60.7(C-6″),56.3(OCH3-7),56.7(OCH3-3′,5′)。
菠萝黄酮苷D(ananaflavoside D,5,6,4′-trihydroxy-7,3′,5′-trimethoxyflavone-6-O-β-D-glucopyranoside)。黄色粉末,mp206℃;
UV(MeOH)nm:339,255,221;
HRFABMS:m/z521.1306[M-1]-(calcd for C24H25O13,521.1300);
1H-NMR(DMSO-d6):13.06(OH-5),9.31(OH-4′),7.38(H-2′,6′),7.03(H-3),6.98(H-8),5.15(H-1″),3.92(OCH3-7),3.91(OCH3-3′,5′);
13C NMR(DMSO-d6):163.9(C-2),103.4(C-3),182.3(C-4),151.6(C-5),128.2(C-6),158.5(C-7),91.8(C-8),152.6(C-9),105.0(C-10),120.3(C-1′),104.4(C-2′),148.2(C-3′),140.0(C-4′),148.2(C-5′),104.3(C-6′),102.0(C-1″),74.1(C-2″),76.6(C-3″),69.9(C-4″),77.4(C-5″),60.9(C-6″),56.4(OCH3-7),56.6(OCH3-3′,5′)。
本发明所提供的化合物菠萝黄酮苷的用途是在制备治疗体内过氧化物升高及其由此引起的疾病的药物中的应用。
本发明所提供的化合物菠萝黄酮苷的用途是在制备治疗体内氧化型低密度脂蛋白和高密度脂蛋白升高的药物中的应用。
所述的化合物作为药物使用时,可以是单独应用,也可以是与其它成分混合使用。
在临床应用时,以常规的制剂工艺,单独使用或与其他药物配合制备成在临床上可以使用的各种不同剂型的药物。如散剂,丸剂,胶囊剂,片剂,微囊剂,软胶囊剂,膜剂,栓剂,注射剂,膏剂,酊剂,散剂,冲剂,气雾剂,各种外用制剂等。
在多年的研究中,本发明人从菠萝叶中分离制备出一组新的化合物---菠萝黄酮苷。药理实验表明,菠萝黄酮苷A-D具有抗氧化和抑制氧化型低密度脂蛋白升高的作用,可以用来治疗体内过氧化物升高所引起的病症,以及低密度脂蛋白升高所引起的相关性疾病,如脂代谢紊乱,动脉粥样硬化,冠心病等。实验结果表明,菠萝黄酮苷A-D具有明显的抑制脑过氧化物MDA升高的作用。体外给药,最小有效终浓度为1×10-6g/ml,随着浓度的增加,抑制作用增强。体外给药,能够明显抑制氧化型低密度脂蛋白的生成,有效浓度为0.3-3ug/ml。
附图说明
图1为本发明所提供的化合物菠萝黄酮苷A-D的化学结构式。
具体实施方式
先将药材重量的5~10倍的醇溶剂在50℃~90℃下进行加热提取,得到提取液;将提取液在50~90℃温度下减压浓缩后,用药材重量的2~5倍水溶解,离心或静止过滤,弃去沉淀,取上清液;将上清液通过大孔吸附树脂,先用水洗脱,洗脱液废弃,再用浓度大于70%的乙醇洗脱,将洗脱液在温度50~90℃下减压浓缩,然后减压干燥或冷冻干燥,得到菠萝叶提取物;将菠萝叶提取物用乙醇溶剂溶解,再用硅胶拌样,用硅胶柱色谱分离,用氯仿:甲醇或石油醚:丙酮或氯仿:丙酮梯度洗脱,用葡聚糖凝胶纯化,先后得到化合物---菠萝黄酮苷A、B、C、D。
菠萝黄酮苷A-D分离制备的来源植物,可以是菠萝叶,也包括其它任何一种植物。
在药剂应用上就是将菠萝黄酮苷A-D单独地或者加入复方中以常规的制剂工艺制备成药剂。其药剂可以是临床上能够使用的各种不同剂型。
下述药物实验资料使本发明所说的菠萝黄酮苷的制备及其用途得以证实,同时又不应将下列实施例看作是对本发明的限制。
实施例1:菠萝黄酮苷A的分离制备及其理化和波谱数据
首先用药材重量的5倍的80%乙醇将菠萝叶在50℃加热提取3次,每次为1小时。然后提取液在减压(压力98Kpa),温度在50℃浓缩后,用药材重量的2倍水溶解,离心,弃去沉淀,上清液通过大孔吸附树脂,先用水洗脱,洗脱液废弃,再用80%乙醇洗脱,洗脱液在温度为50℃(压力98Kpa)减压浓缩,浓缩物减压(压力98Kpa)干燥,得到菠萝叶提取物。菠萝叶提取物用60%乙醇溶解,再用硅胶拌样,用硅胶柱色谱分离,石油醚:丙酮梯度洗脱,用葡聚糖凝胶纯化,先得到该化合物---菠萝黄酮苷A。
理化性质和波谱特征:
菠萝黄酮苷A(ananaflavoside A,5,4′-dihydroxy-7,3′,5′-trimethoxyflavone-4′-O-β-D-glucopyranoside):黄色粉末,mp196-198℃;
UV(MeOH)nm:321,273,220;
HRFABMS:m/z 507.1490[M+1]+(calcd for C24H27O12,507.1496);
1H NMR(DMSO-d6):12.86(OH-5),7.37(H-2′,6′),7.14(H-3),6.78(H-8)6.39(H-6),5.15(H-1″),3.88(OCH3-3′,5′),3.87(OCH3-7);
13CNMR(DMSO-d6):163.3(C-2),104.8(C-3),182.1(C-4),161.1(C-5),98.1(C-6),165.3(C-7),92.9(C-8),157.5(C-9),105.0(C-10),121.5(C-1′),104.3(C-2′),148.2(C-3′),137.7(C-4′),148.2(C-5′),104.3(C-6′),101.9(C-1″),74.1(C-2″),76.6(C-3″),69.8(C-4″),77.4(C-5″),60.7(C-6″),56.1(OCH3-7),56.7(OCH3-3′,5′)。
实施例2:菠萝黄酮苷B的分离制备及其理化和波谱数据
首先用药材重量的6倍的70%乙醇将菠萝叶在60℃加热提取2次,每次为1小时。然后提取液在减压(压力98Kpa),温度在50℃浓缩后,用药材重量的2倍水溶解,离心,弃去沉淀,上清液通过大孔吸附树脂,先用水洗脱,洗脱液废弃,再用80%乙醇洗脱,洗脱液在温度为50℃(压力98Kpa)减压浓缩,浓缩物减压(压力98Kpa)干燥,得到菠萝叶提取物。菠萝叶提取物用70%乙醇溶解,再用硅胶拌样,用硅胶柱色谱分离,氯仿:甲醇梯度洗脱,用葡聚糖凝胶纯化,继菠萝黄酮苷A后得到该化合物---菠萝黄酮苷B。
理化性质和波谱特征:
菠萝黄酮苷B(ananaflavoside B,5,4′-dihydroxy-6,7,3′,5′-tetramethoxyflavone-4′-O-β-D-glucopyranoside):黄色粉末,mp206-207℃;
UV(MeOH)nm:328,281,220;
HRFABMS:m/z 537.1607[M+1]+(calcd for C25H29O13,537.1602);
1H NMR(DMSO-d6):12.84(OH-5),7.38(H-2′,6′),7.14(H-3),7.02(H-8),5.15(H-1″),3.87(OCH3-7),3.89(OCH3-3′,5′),3.60(OCH3-6);
13CNMR(DMSO-d6):163.2(C-2),104.6(C-3),182.3(C-4),152.9(C-5),131.9(C-6),158.7(C-7),91.8(C-8),152.7(C-9),105.2(C-10),125.5(C-1′),104.9(C-2′),152.8(C-3′),137.6(C-4′),152.8(C-5′),104.9(C-6′),101.8(C-1″),74.1(C-2″),76.5(C-3″),69.8(C-4″),77.4(C-5″),60.7(C-6″),60.0(OCH3-6),56.5(OCH3-7),56.7(OCH3-3′,5′)。
实施例3:菠萝黄酮苷C的分离制备及其理化和波谱数据
首先用药材重量的7倍的60%乙醇将菠萝叶在70℃加热提取3次,每次为2小时。然后提取液在减压(压力98Kpa),温度在50℃浓缩后,用药材重量的2倍水溶解,离心,弃去沉淀,上清液通过大孔吸附树脂,先用水洗脱,洗脱液废弃,再用80%乙醇洗脱,洗脱液在温度为50℃(压力98Kpa)减压浓缩,浓缩物减压(压力98Kpa)干燥,得到菠萝叶提取物。菠萝叶提取物用50%乙醇溶解,再用硅胶拌样,用硅胶柱色谱分离,氯仿:丙酮梯度洗脱,用葡聚糖凝胶纯化,继菠萝黄酮苷B后得到该化合物---菠萝黄酮苷C。其理化性质和波谱特征:
菠萝黄酮苷C(ananaflavoside C,5,6,4′-trihydroxy-7,3′,5′-trimethoxyflavone-4′-O-β-D-glucopyranoside):黄色粉末,mp153-155℃;
UV(MeOH)nm:329,221,219;
HRFABMS:m/z523.1443[M+1]+(calcd for C24H27O13,523.1446);
1H NMR(DMSO-d6):12.56(OH-5),8.76(OH-6),7.37(H-2′,6′),7.09(H-3),7.00(H-8),5.14(H-1″),3.93(3H,s,OCH3-7),3.89(OCH3-3′,5′);
13CNMR(DMSO-d6):162.9(C-2),104.4(C-3),182.3(C-4),146.0(C-5),130.0(C-6),154.4(C-7),91.3(C-8),149.7(C-9),105.1(C-10),125.2(C-1′),104.8(C-2′),152.8(C-3′),137.5(C-4′),152.8(C-5′),104.8(C-6′),101.9(C-1″),74.1(C-2″),76.5(C-3″),69.8(C-4″),77.4(C-5″),60.7(C-6″),56.3(OCH3-7),56.7(OCH3-3′,5′)。
实施例4:菠萝黄酮苷D的分离制备及其理化和波谱数据
首先用药材重量的10倍的50%乙醇将菠萝叶在70℃加热提取3次,每次为3小时。然后提取液在减压(压力98Kpa),温度在50℃浓缩后,用药材重量的2倍水溶解,离心,弃去沉淀,上清液通过大孔吸附树脂,先用水洗脱,洗脱液废弃,再用80%乙醇洗脱,洗脱液在温度为50℃(压力98Kpa)减压浓缩,浓缩物减压(压力98Kpa)干燥,得到菠萝叶提取物。菠萝叶提取物用80%乙醇溶解,再用硅胶拌样,用硅胶柱色谱分离,石油醚:丙酮梯度洗脱,用葡聚糖凝胶纯化,继菠萝黄酮苷C后得到该化合物---菠萝黄酮苷D。其理化性质和波谱特征:菠萝黄酮苷D:(ananaflavoside D,5,6,4′-trihydroxy-7,3′,5′-trimethoxyflavone-6-O-β-D-glucopyranoside)。黄色粉末,mp206℃;
UV(MeOH)nm:339,255,221;
HRFABMS:m/z521.1306[M-1]-(calcd for C24H25O13,521.1300);
1H NMR(DMSO-d6):13.06(OH-5),9.31(OH-4′),7.38(H-2′,6′),7.03(H-3),6.98(H-8),5.15(H-1″),3.92(OCH3-7),3.91(OCH3-3′,5′);
13C NMR(DMSO-d6):163.9(C-2),103.4(C-3),182.3(C-4),151.6(C-5),128.2(C-6),158.5(C-7),91.8(C-8),152.6(C-9),105.0(C-10),120.3(C-1′),104.4(C-2′),148.2(C-3′),140.0(C-4′),148.2(C-5′),104.3(C-6′),102.0(C-1″),74.1(C-2″),76.6(C-3″),69.9(C-4″),77.4(C-5″),60.9(C-6″),56.4(OCH3-7),56.6(OCH3-3′,5′)。
实施例5:对脑MDA生成的影响
观察本发明菠萝黄酮苷对小鼠脑MDA生成的抑制作用。本发明所用菠萝黄酮苷A-D,批号:990418。用时以生理盐水配制成所需浓度。实验所用动物为雄性ICR小鼠,非近交系封闭群,北京维通利华实验动物技术有限公司提供,合格证号:SCXK(京)2002-0003,体重18-22g。实验室室温20-22℃,相对湿度40%~60%,换气扇通气,自然光源12h/日,笼养,每笼10只,每三日清扫笼舍一次。
取正常小鼠,处死后取脑,加入生理盐水做匀浆液(与脑比例为5∶1)。4℃冰箱静置5分钟,取上部均匀混浊液。每管加入脑组织液150uL,加入不同浓度药液50ul,37℃水浴孵育30分。依次加入10%SDS0.1ml,50%冰醋酸硫代巴比妥酸液0.5ml和1%盐酸液2ml。沸水浴15分钟,取出后冷水置10分钟,1500转离心15分钟,取上清于532nm处测吸光度A值。每组做三复管。计算抑制率=[(对照组A-给药组A)/对照组A×100%]。
所得数据经EXCEL软件处理。组间t检验。
本试验菠萝黄酮苷A-D给药终浓度分别为1×10-4g/ml,1×10-5g/ml,1×10-6g/ml。
本试验为体外实验。本试验空白对照为等体积生理盐水。阳性药对照为维生素E,购自Sigma公司。实验终浓度为1×10-5g/ml。本试验数据均以Excel软件处理。
表1:菠萝黄酮苷体外对脑MDA生成的抑制作用(x±s)
分组 | 药物终浓度(g/ml) | Umol/g |
生理盐水维生素C菠萝黄酮苷A菠萝黄酮苷A菠萝黄酮苷A菠萝黄酮苷B菠萝黄酮苷B菠萝黄酮苷B菠萝黄酮苷C菠萝黄酮苷C | 1×10-31×10-41×10-51×10-61×10-41×10-51×10-61×10-41×10-5 | 104.43±9.9542.38±1.66**42.47±1.84**59.6±5.92**69.77±5.09**41.93±1.76**58.7±5.11**67.38±3.93**47.91±4.06**60.7±3.83** |
菠萝黄酮苷C菠萝黄酮苷D菠萝黄酮苷D菠萝黄酮苷D | 1×10-61×10-41×10-51×10-6 | 66.49±5.55**56.05±4.4**59.0±3.28**78.39±6.22* |
与生理盐水组相比,*P<0.05,**P<0.01。n=3
本实验结果显示,菠萝黄酮苷A-D体外有较强地抑制缺糖缺氧脑组织MDA生成的作用,最低有效浓度为1×10-6g/ml。提示菠萝黄酮苷A-D具有一定的抗氧化的作用。
实施例6:体外对氧化型低度脂蛋白升成的抑制作用
本发明所用雄性家兔,体重2.26±0.47Kg。由中国医学科学院阜外医院动物室提供。合格证号:京动管质字(96)第006号。
本发明试验LDL的提取制备。25%的乌拉坦耳缘静脉麻醉(2ml-4ml/kg),耳静脉体内肝素抗凝,颈总动脉取血100ml左右,用终浓度为0.4mg/ml的EDTA抗氧化。1500rpm离心10min,取血浆。
配密度梯度液:
d=1.0即0液的配制:0.01%EDTA,PH=7.4-8.0
d=1.1液的配制:取0液100mL+NaBr13.5g
d=1.2液的配制:取0液100mL+NaBr29.5g
d=1.21液的配制取0液100mL+NaBr30g
d=1.3液的配制:取血浆100mL+NaBr40g
铺梯度密度层:先用长针头管吸取0液7mL铺于容量为25.9mL的Beckman离心管底部,而后小心将吸取了约7mL的d=1.1液长针头插入Beckman试管底部缓缓加入液体,使0液上浮,余下依此法加入d=1.3液的血浆,注意一定要使各液面分层。
超速离心:角度转头Ti50.2,XL-90Beckman离心管25.9mL,45000rpm,1.4h,10℃。
透析:
透析袋的处理:以2%(W/V)NaHCO3+1mmoL/LEDTA(PH8.0)1000mL煮10分钟(称2gNaHCO3溶于100mLD.W.中,称0.37gEDTA溶于1000mLD.W.中即可)。用重蒸馏水洗后,再用1mmoL/LEDTA(PH8.0)煮10分钟。冷至4℃备用。用前用重蒸馏水透析袋洗内壁。
透析液配制:0.85%NaCl 8.5g,0.02Mtris-HCl 2.42g,0.01%EDTA 0.1g,0.03%NaN30.3g,共1000mL(pH7.4)。
透析条件:避光,密闭,4℃,24h,换4-5次液。
将PEG-20000覆盖于透析袋上,随时观察浓缩情况(一般浓缩为1mg/mL左右)。
蛋白定量。用1.0mg/mL的牛血清白蛋白为标准品,于UV-280nm处测LDL中蛋白浓度。将LDL蛋白浓度稀释到0.25mg/mL,2mL。用时2倍稀释,即蛋白浓度0.125mg/mL。每个剂量做3复管。
LDL测试。取0.125mg/mL的LDL的液内加入测试药物,即时测OD值,然后水浴(20℃)30分钟后加入CuSO4H2O 5umoL/L,水浴30分钟后测定OD234mm,以加入CuSO4H2O后30分钟的OD值与加入CuSO4H2O前所测OD值的差值[OD(30分钟)-OD(0分钟)],表明其氧化型低密度脂蛋白生成的速率,以此反应药物的抑制作用。
本发明所用蒸馏水为空白对照。阳性对照药为维生素C(分析纯),批号:011206。北京芳草医药化工研制公司生产。
结果:
表2:不同药物对氧化低密脂蛋白生成的影响(x±s)
剂量(ug/ml) | OD(30分钟)-OD(0分钟) | |
生理盐水模型+生理盐水模型+维生素C模型+菠萝黄酮苷A模型+菠萝黄酮苷A模型+菠萝黄酮苷B模型+菠萝黄酮苷B模型+菠萝黄酮苷C模型+菠萝黄酮苷C模型+菠萝黄酮苷D模型+菠萝黄酮苷D | 0.50.330.330.330.33 | 0.008±0.00260.0963±0.0121##0.03±0.0075**0.05±0.0114*0.0263±0.0116**0.0437±0.0074*0.0157±0.006**0.0493±0.0116*0.0333±0.0075**0.065±0.013*0.0453±0.0055** |
与生理盐水组相比,##P<0.01。与模型+生理盐水组相比,*P<0.05,**P<0.01。n=3。
菠萝黄酮苷A-D在终浓度为0.3,3ug/ml时,对Cu2SO4诱导的LDL氧化为氧化型LDL(ox-LDL)有明显的抑制作用。阳性对照药VC,具有明显的抑制ox-LDL产生的作用。已知ox-LDL对于动脉平滑肌有明显的侵蚀作用,它可以使内皮细胞受损,从而使血管内壁受损,而使血栓形成并附壁。因此菠萝黄酮苷苷A-D的这种抑制ox-LDL的作用对于防止冠心病和脑血栓具有重要的临床意义。
Claims (3)
1.化合物菠萝黄酮苷,其化学结构通式如下:
其中:
菠萝黄酮苷A:R1=H R2=O-β-D-Glc
菠萝黄酮苷B:R1=OCH3 R2=O-β-D-Glc
菠萝黄酮苷C:R1=OH R2=O-β-D-Glc
菠萝黄酮苷D:R1=O-β-D-Glc R2=OH
2.如权利要求1所述化合物菠萝黄酮苷在制备治疗体内过氧化物升高及由此引起的疾病的药物中的用途。
3.如权利要求1所述化合物菠萝黄酮苷在制备治疗体内氧化型低密度脂蛋白升高的药物中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410009055 CN1246326C (zh) | 2004-04-29 | 2004-04-29 | 化合物菠萝黄酮苷及用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN 200410009055 CN1246326C (zh) | 2004-04-29 | 2004-04-29 | 化合物菠萝黄酮苷及用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1569868A CN1569868A (zh) | 2005-01-26 |
CN1246326C true CN1246326C (zh) | 2006-03-22 |
Family
ID=34477785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN 200410009055 Expired - Fee Related CN1246326C (zh) | 2004-04-29 | 2004-04-29 | 化合物菠萝黄酮苷及用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1246326C (zh) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ594754A (en) | 2005-11-29 | 2013-03-28 | Bio Actives Exp Pty Ltd | Biologically active compounds derived from Centipeda cunninghamii |
CN101648980B (zh) * | 2009-08-28 | 2013-01-30 | 广东轻工职业技术学院 | 以菠萝皮为原料联合制取菠萝多酚与果汁的方法及其应用 |
CN104974202B (zh) * | 2015-06-26 | 2017-11-28 | 广西中医药大学 | 一种从天然产物中提取分离牡荆素木糖苷的方法 |
CN105254691B (zh) * | 2015-10-27 | 2018-07-06 | 中国科学院华南植物园 | 一种制备2”-O-β-D-xylosylvitexin的方法 |
CN111714570A (zh) * | 2020-05-09 | 2020-09-29 | 广州大学 | 一种菠萝果皮黄酮的分离纯化方法及黄酮 |
-
2004
- 2004-04-29 CN CN 200410009055 patent/CN1246326C/zh not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
CN1569868A (zh) | 2005-01-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2006512330A (ja) | 竹からの抽出のトリテルペノイドサポゲニン化合物の製法と用途 | |
CN106937959B (zh) | 一种抗肿瘤海蟑螂提取物及其制备工艺与检测方法与用途 | |
CN1891240A (zh) | 一种含多种灵芝活性成分的中药组合物及其制备方法 | |
CN1850836A (zh) | 一类青葙皂苷类化合物及其在医药领域的应用 | |
JP2016102111A (ja) | 補助化療薬品とされる医薬組成物その用途 | |
WO2017092230A1 (zh) | 双黄酮化合物及其治疗癌症和制备药物的用途 | |
CN102276619A (zh) | 斑蝥酸钠的制备方法 | |
CN1246326C (zh) | 化合物菠萝黄酮苷及用途 | |
Wang et al. | The therapeutic potential of arctigenin against multiple human diseases: a mechanistic review | |
CN104224863B (zh) | 金钱草总黄酮在制备治疗高尿酸血症药物中的应用 | |
CN1230160C (zh) | 竹叶总黄酮在制备前列腺疾病防治药物中的应用 | |
CN1883286A (zh) | 一种茶奶及其制备方法 | |
CN105012356B (zh) | 灵芝酸a在抗抑郁症中的用途 | |
CN101396373B (zh) | 一种华蟾素提取物及其制备方法 | |
CN1188406C (zh) | 蒲黄提取物及其制备方法和用途 | |
CN1687092A (zh) | 苍耳子总苷提取物及其制备方法 | |
CN115444893A (zh) | 一种降尿酸活性物质组合物及其应用 | |
CN1238333C (zh) | 药物化合物菠萝酰酯及其制备方法和用途 | |
CN112807292A (zh) | 白首乌二苯酮在制备降尿酸药物中的应用 | |
CN106074643B (zh) | 红毛五加叶及其提取物在制备抗疲劳的药物或保健食品中的用途 | |
CN105497167A (zh) | 猫爪草在制备治疗和/或预防溃疡性结肠炎药物方面的新用途 | |
CN1258536C (zh) | 化合物菠萝酸苷及其用途 | |
CN100434085C (zh) | 鸦胆子油毒性成分的去除方法 | |
CN111053819A (zh) | 中药组合物提取物及在制备蛋白表达调节剂中的应用 | |
CN104130232B (zh) | 一种egcg的提纯方法及获得的egcg和药物组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
C19 | Lapse of patent right due to non-payment of the annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |